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Objectives: The aim of this study was to prospectively assess the pattern of evolution of primary resistance to
antibiotics in Helicobacter pylori strains isolated from Portuguese children over a 10 year period (2000–09).
Methods: A total of 1115 H. pylori strains were tested for antibiotic susceptibility to clarithromycin, metronida-
zole, amoxicillin, ciprofloxacin and tetracycline.
Results: H. pylori strains were isolated from children and adolescents [ages 4 months–18 years (mean age
10.17+4.03 years)], comprising 562 (50.4%) boys and 553 (49.6%) girls. Overall, the primary resistance rate
was 34.7% to clarithromycin, 13.9% to metronidazole and 4.6% to ciprofloxacin, while 6.9% were resistant
to two of these antibiotics simultaneously. Resistance to amoxicillin and to tetracycline was not detected. In
general, the resistance rate was not associated with gender or the children’s age. European ethnicity, when
compared with an African background, was associated with clarithromycin resistance [P¼0.002; odds ratio
(OR)¼0.30; 95% confidence interval (CI) 0.14–0.66], while the inverse situation was observed for metronida-
zole (P,0.001; OR¼3.50; 95% CI 1.90–6.45). No significant temporal trend was noticed for resistance to clar-
ithromycin and metronidazole, whereas ciprofloxacin and double-resistance rates have significantly increased
over time (P¼0.004 and P¼0.05, respectively).
Conclusions: The primary resistance rate of H. pylori strains isolated from Portuguese children to the commonly
used anti-H. pylori antibiotics used is high. Additionally, the increasing trend of ciprofloxacin-resistant and
double-resistant strains may compromise H. pylori eradication in a high-prevalence population.
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Introduction
Helicobacter pylori colonizes the human gastric mucosa of more
than 50% of the world’s population, with infection always elicit-
ing an acute immune response that fails, however, in achieving
spontaneous eradication.1 The lifelong persistence of this infec-
tion may result in the development of non-ulcer dyspepsia
(NUD), which may further progress to severe gastric diseases,
such as peptic ulcer disease (PUD) and two forms of gastric
cancer [adenocarcinoma and mucosa-associated lymphoid
tissue (MALT) lymphoma].2
The most common first-line regimen for the eradication of
H. pylori consists of a combination of clarithromycin or metroni-
dazole, with amoxicillin, plus a proton pump inhibitor (PPI). Pro-
posed rescue treatment regimens include the use of
fluoroquinolones, tetracyclines or rifamycin-based therapies.
Considering both the large percentage of the infected population
and the high and increasing rates of antibiotic resistance
reported worldwide, the issue of treatment is thus currently
unsolved and particularly problematic.3
The actual prevalence of H. pylori antibiotic resistance among
children in Portugal is not known. The present study aimed to
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prospectively assess the pattern of evolution of primary resist-
ance to antibiotics in H. pylori strains isolated from Portuguese
children over a 10 year period (2000–09), as well as identify
the possible associated factors.
Methods
Patients and H. pylori strains
From January 2000 to December 2009, a total of 1115 H. pylori strains
were prospectively isolated from Portuguese children and adolescents
attending the three Paediatric Gastroenterology Units in the Lisbon
area for severe and/or recurrent upper gastrointestinal symptoms sug-
gestive of organic disease and considered sufficiently relevant to justify
an upper endoscopy and antibiotic treatment. Demographic and clinical
data were collected retrospectively. None of the patients had been
treated for H. pylori infection before endoscopy. Clinical strains were cul-
tured from a pool of colonies from antral biopsy specimens.
Antibiotic susceptibility testing
Susceptibility testing was performed using Etest (bioMe´rieux, Marcy
l’E´toile, France) for clarithromycin, metronidazole and amoxicillin, and
by disc diffusion (Oxoid, Hampshire, UK) for ciprofloxacin and tetracycline.
The MIC breakpoints used were ≥1 mg/L for clarithromycin, .8 mg/L for
metronidazole and.0.5 mg/L for amoxicillin, according to previous refer-
ences.4 By disc diffusion, strains were classified as resistant if growth inhi-
bition zones were ,20 mm for ciprofloxacin (5 mg) and ,17 mm for
tetracycline (30 mg) [Comite´ de l’Antibiogramme de la Socie´te´ Franc¸aise
de Microbiologie, Recommendations 2010 (Edition de Janvier 2010),
http://www.sfm.asso.fr/].
Statistical analysis
Statistical analysis was performed with the statistical package PASW
Statistics version 18.01 (IBM SPSS Statistics, release 18.0, July 2009).
Pearson’s x2 test and 95% confidence intervals (CIs) were used. Identifi-
cation of variables associated with H. pylori antibiotic resistance was per-
formed by univariate logistic regression and confirmed by multiple
logistic regression analysis. The level of significance was set at 5%.
Results
Population characteristics
Within a 10 year observation period, 1115H. pylori strains were iso-
lated from children and adolescents, ages 4 months–18 years
(mean age 10.17+4.03 years), comprising 562 (50.4%) boys
and 553 (49.6%) girls. Children were stratified into three age
groups: 0–5 years (163, 14.6%); 6–10 years (430, 38.6%); and
11–18 years (522, 46.8%). Information on ethnicity was available
for 615 (55.2%) children, with the following distribution: 554
(90.1%) European [mostly Portuguese (98%)], 53 (8.6%) African
and 8 (1.3%) Asian or Caucasian/European. According to clinical
outcome, most of the children (96%, n¼1069) presented with
NUD (comprising severe recurrent abdominal pain, reflux-like dys-
pepsia, vomiting, coeliac disease and unexplained refractory side-
ropenic anaemia) and 4.0% (n¼44) had PUD. This latter condition
was significantly more common in older children [5.4% versus
2.8%; P¼0.021; odds ratio (OR)¼2.12; 95% CI 1.13–3.99] and
also in boys (63.6% versus 36.4%; P¼0.025; OR¼2.04; 95% CI
1.09–3.82).
Antibiotic resistance
Overall, the primary resistance rate of H. pylori was 34.7%
(n¼387) to clarithromycin (median MIC 0.016 mg/L, range
0.016–256), 13.9% (n¼155) to metronidazole (median MIC
0.25 mg/L, range 0.016–256) and 4.6% (n¼51) to ciprofloxacin.
Simultaneous resistance to two of these antibiotics occurred in
6.9% (n¼76) of the isolates, of which 72.4% (n¼55) were resist-
ant to both clarithromycin and metronidazole, 23.7% (n¼18) to
both clarithromycin and ciprofloxacin, and 3.9% (n¼3) to metro-
nidazole and ciprofloxacin. One strain was simultaneously resist-
ant to these three antibiotics. Resistance to amoxicillin (median
MIC 0.016 mg/L, range 0.016–0.5) and tetracycline was not
found.
No overall significant trend for resistance to clarithromycin or
metronidazole was noticed. Indeed, considering three time
periods, 2000–02 (n¼191), 2003–05 (n¼320) and 2006–09
(n¼604), a stationary trend could be observed for both these
antibiotics (Table 1), although between 2000–02 and 2003–
05, a significant decrease in the metronidazole resistance rate
was observed (P¼0.037) (Table 1). The clarithromycin and
metronidazole MIC values were also stable throughout the
time period studied (data not shown).
In contrast, the resistance rate to ciprofloxacin has been signifi-
cantly rising over time, particularly during the period 2006–09
(P¼0.004), and the same scenario has been observed for the
double-resistant strains (P¼0.050) (Figure 1).
The univariate analysis showed that, overall, there was no
association of resistance to clarithromycin, metronidazole or
ciprofloxacin with children’s gender or disease outcome
(Table 1), except that metronidazole resistance was more
common in older children (group aged 11–18 years), particularly
when comparing with the youngest children (13.7% versus 9.9%,
respectively; P¼0.051; OR¼1.76; 95% CI 1.00–3.10). Resistance
to clarithromycin was associated with European ethnicity, when
compared with an African background (37.0% versus 15.1%,
respectively; P¼0.002; OR¼0.30; 95% CI 0.14–0.66), while,
inversely, resistance to metronidazole was more common
among African children (35.8% versus 13.8%, respectively;
P,0.001; OR¼3.50; 95% CI 1.90–6.45). No significantly
related factors were related to ciprofloxacin and double resist-
ance (Table 1). All the associations found were confirmed by
multiple logistic regression analysis (data not shown).
Discussion
The present study, concerning primary resistance to antibiotics of
H. pylori strains isolated between 2000 and 2009 from 1115
Portuguese children, shows that the overall resistance rate
remains high, in particular to clarithromycin (34.7%). These
data are corroborated by a recent European multicentre study
on antibiotic resistance of H. pylori strains showing that children
from south Europe presented a significant risk for primary clari-
thromycin resistance, which is likely a consequence of a recog-
nized overuse in the past and the persistent use nowadays of
macrolides for the treatment of upper respiratory tract infections
in those countries.4 In our study, the only factor associated with
clarithromycin resistance was European ethnicity, compared with
an African background, as shown in previous studies.4 – 6 The high
H. pylori clarithromycin primary resistance recently reported in
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children from several European countries, as well as from other
parts of the developed world, emphasizes that this is a
common problem in these populations.3 – 6
The metronidazole primary resistant rate observed in our
study (13.9%) was about 2-fold lower than the average rate
reported for European children.4 – 7 This discrepancy may be
Table 1. Univariate analysis of factors associated with H. pylori primary resistance to clarithromycin, metronidazole and ciprofloxacin among
paediatric patients
Variable Description
Resistance to clarithromycin
[% resistant, OR (95% CI)] Pa
Resistance to metronidazole
[% resistant, OR (95% CI)] Pa
Resistance to ciprofloxacin
[% resistant, OR (95% CI)] Pa
Gender,
n¼1115
0.451 0.863 0.887
male 33.6%, 1 (ref) 12.6%, 1 (ref) 4.5%, 1 (ref)
female 35.8%, 1.10 (0.86–1.41) 0.446 14.2%, 1.04 (0.74–1.46) 0.836 4.7%, 1.06 (0.60–1.85) 0.850
Age (years),
n¼1115
0.731 0.055 0.831
,6 34.8%, 1 (ref) — 9.9%, 1 (ref) — 3.8%, 1 (ref) —
6–10 33.3%, 0.93 (0.64–1.37) 0.727 12.0%, 1.22 (0.68–2.24) 0.484 5.0%, 1.33 (0.53–3.36) 0.544
11–18 35.7%, 1.04 (0.72–1.51) 0.829 13.7%, 1.76 (1.00–3.10) 0.051 4.7%, 1.24 (0.50–3.10) 0.639
Ethnic group,
n¼615
0.006 <1023 0.358
European 37.0%, 1 (ref) — 13.8%, 1 (ref) — 4.7%, 1 (ref) —
African 15.1%, 0.30 (0.14–0.66) 0.002 35.8%, 3.50 (1.90–6.45) <1023 1.9%, 0.39 (0.05–2.91) 0.357
other 37.5%, 1.02 (0.24–4.32) 0.977 12.5%, 0.90 (0.11–7.37) 0.918 12.5%, 2.88 (0.34–24.28) 0.331
Gastric disease,
n¼1113
0.106 0.376 1.000
PUD 22.7%, 1 (ref) — 18.2%, 1 (ref) — 4.5%, 1 (ref) —
NUD 35.2%, 0.54 (0.27–1.11) 0.094 13.7%, 1.40 (0.64–3.07) 0.401 4.6%, 0.98 (0.23–4.18) 0.982
Time period,
n¼1115
0.211 0.074 0.004
2000–02 33.5%, 1 (ref) — 16.8%, 1 (ref) — 1.6%, 1 (ref) —
2003–05 31.3%, 0.90 (0.62–1.32) 0.597 10.3%, 0.57 (0.34–0.97) 0.037 2.8%, 1.81 (0.48–6.77) 0.378
2006–09 36.9%, 1.16 (0.82–1.64) 0.392 15.0%, 0.87 (0.56–1.36) 0.547 6.5%, 4.35 (1.33–14.24) 0.015
ref, reference category.
aP value obtained by univariate logistic model.
Statistically significant P values (,0.05) are highlighted in bold.
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Figure 1. Temporal trend for H. pylori resistance to ciprofloxacin and to two of the antibiotics simultaneously (clarithromycin, metronidazole or
ciprofloxacin), considering three time periods: 2000–02 (00–02, n¼191), 2003–05 (03–05, n¼320) and 2006–09 (06–09, n¼604).
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only partially explained by the lower percentage of children with
African ethnicity (8.6%) than that reported in other studies. This
result also contrasts with the high primary resistance seen
among Portuguese adults (32.3%),8 and likely reflects differ-
ences in metronidazole consumption according to the patient’s
age. Indeed, the lack of a metronidazole paediatric formulation
in Portugal may discourage parents to treat their children, result-
ing in less exposure to this antibiotic.
The high rate of metronidazole resistance detected in our
study among African children (35.8%) is in agreement with
other reports and consistent with its extensive use for treating
parasitic diseases in tropical countries.4 Metronidazole resistance
was also associated with older age, which has not been com-
monly reported. Indeed, association with age has been described
for clarithromycin, but in the opposite sense, i.e. associated with
younger age,4 although in our study, as well as in other studies,
this correlation was not found.5,6
Data on H. pylori quinolone resistance in children is scarce.
Nevertheless, the global primary resistance rate to ciprofloxacin
observed in our study (4.6%) was higher than that reported in
children from Spain (ciprofloxacin, 2/66, 3.6%) or Austria (levo-
floxacin, 0%).6,7 Moreover, it has been increasing at an alarming
rate over time, reaching almost 7% in the last period studied
(2006–09). These results are consistent with data on quinolone
consumption among 25 European countries, showing that
southern countries presented the highest outpatient use of qui-
nolones, with Portugal occupying the first place.9
In conclusion, this is the first H. pylori antibiotic resistance
multicentre study ever conducted in Portugal, comprising a
large number of infected children. We emphasize the findings
of high primary resistance rates to the antibiotics most com-
monly used in the first-line H. pylori eradication treatment
schemas, with a negative clinical impact in the management
of this infection. Furthermore, the increasing detection rate of
ciprofloxacin and double-resistant strains over time warrants
specific attention and continued surveillance, as it may compro-
mise the efficacy of second-line schemas in the paediatric age
group, representing a serious public health problem in popu-
lations with a high prevalence of H. pylori infection, such as the
Portuguese population.10
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